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The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case
presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and
a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how
to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own
clinical practice.
An 84-year-old woman presented with bone pain and lytic bone lesions in April 2010. Diagnosis of multiple
myeloma was based on the presence of an immunoglobulin G lambda serum M protein (4,784 mg/dL) and
confirmed by the findings of bone marrow plasma cell infiltration, with t(11;14) chromosomal abnormality
detected by fluorescence in situ hybridization analysis. The patient’s medical history was significant for
hypertension; she had an Eastern Cooperative Oncology Group performance status of 1, International
Staging System (ISS) stage of 1, and Durie–Salmon stage of IIIA. In May 2010, the patient was enrolled in
a randomized phase III trial comparing different lenalidomide-based treatments and received induction
with lenalidomide plus dexamethasone (nine cycles) followed by lenalidomide maintenance. The patient
started treatment with lenalidomide 25 mg per day for 21 days and reduced-dose dexamethasone 20 mg per
week per protocol because of age. Induction was well tolerated; no relevant complications occurred, except
for grade 1 fatigue and grade 1 diarrhea. Best response was partial response. In March 2011, she started
maintenance with lenalidomide 10 mg per day. A dose reduction of lenalidomide 5 mg per day was required
because of grade 2 diarrhea. In July 2015, the patient experienced relapse, with painful collapse of L3
vertebral body.
CHALLENGES IN DIAGNOSIS AND MANAGEMENT
Multiple myeloma (MM) is a neoplastic disease deriving from an
abnormal proliferation of monoclonal plasma cells in the bone
marrow and immunoglobulin or light chain overproduction that
can cause end-organ damage.1 Despite recent advances, MM re-
mains incurable. Its natural history is characterized by subsequent
relapses, with shorter disease-free and asymptomatic status in-
tervals, until the disease becomes refractory to therapies.1
MM predominantly affects elderly patients; median age at
diagnosis is 70 years, and almost one third of patients are older
than 75 years of age, with the highest rates of diagnosis reported in
the 80- to 89-year age group.2 The International Staging System
(ISS) stratifies patients into three prognostic groups.3 Chromo-
somal abnormalities, such as deletion 17 or translocations (4;14) and
(14;16), have been found to be associated with poor prognosis.4
Age has long been considered the leading criterion in defining
patients’ treatment. The cutoff age of 65 years defines eligibility
for autologous stem-cell transplantation (ASCT; for patients age
, 65 years) or combination regimens (for patients age$ 65 years).
Since biologic age does not always correspond to chronologic age,
this strict range may differ by approximately 5 years. Patients
. 70 years of age are less likely to benefit from ASCT and
are treated with combination regimens, and elderly patients
(age . 75 years) are treated using gentler approaches, with
therapeutic agents often administered at lower doses than in
younger, fitter patients.5
Melphalan plus prednisone (MP) had long been the reference
treatment for elderly patients, with a median survival of 29 to
37 months.6 In the last decade, new effective treatments, including
novel agents thalidomide, bortezomib, and lenalidomide, have
replaced the formerly standard MP. Current standard treatment of
patients . 65 years of age (or younger with significant comor-
bidities and unsuitable for ASCT) consists of MP plus either
thalidomide (MPT) or bortezomib (VMP).7,8 Recently, continuous
lenalidomide and low-dose dexamethasone (Rd) was shown to be
superior to MPT.9
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Registry data show that 5-year OS has improved markedly in
recent years for patients 45 to 64 years of age; however, less benefit
was seen among patients 65 to 74 years of age, and no improvement
was seen for patients. 75 years of age.10 The elderly population is
highly heterogeneous, and the well-known biologic and genetic
prognostic factors, as well as age per se, are insufficient to explain
this survival difference. One limitation is that elderly patients
usually do not meet eligibility criteria and thus are under-
represented in clinical studies.11
In hemato-oncology, the term frail often improperly refers
to a person . 75 years of age, which sometimes leads to in-
adequate, undertreatment of fit patients or overtreatment of
frail patients based only on age. Currently, chronologic age,
performance status, and clinician judgment are commonly used
in the decision-making process but do not account for the
heterogeneity of the older population.5 Furthermore, geriatric
impairments are highly prevalent in elderly patients (even in
those with good performance status); they may not be easily
detected and may impact a patient’s ability to complete
treatment.12,13
SUMMARY OF THE RELEVANT LITERATURE
Geriatric Assessment
It is crucial to appropriately assess the frailty status of elderly
patients, particularly those . 75 years of age, to identify frail
patients and consequently determine their optimal treatment. An
objective and reproducible tool that could assist clinicians in
tailoring therapy, not only according to disease-specific parameters
but also to a patient’s health status, is fundamental.
The comprehensive geriatric assessment (CGA) is a systematic
procedure to objectively appraise the health status of older people,
focusing on somatic, functional, and psychosocial domains. It is
a highly sensitive and specific tool, and it is more objective and
reliable than clinical judgment.12-14
Recently, the International Myeloma Working Group
(IMWG) conducted a pooled analysis of data on 869 individual
patients from three prospective trials and proposed a score for
the measurement of frailty in elderly patients with newly di-
agnosed MM. At diagnosis, a simplified geriatric assessment
was performed including: the Activity of Daily Living (ADL)
and the Instrumental Activity of Daily Living (IADL) scales to
assess self-care activities, household management tasks, in-
dependence status, and the Charlson comorbidity index to
evaluate the number and severity of comorbidities. The cutoff
age to define frail patients was established at 80 years of age. An
additive scoring system (range, 0 to 5) based on age and these
three tools was developed, and three groups of patients were
identified: fit (score, 0; 39%), intermediate (score, 1; 31%), and
frail (score, $ 2; 30%). Frailty was associated with inferior
overall survival (OS; 3-year OS, 57% v 84%; P 5 .042),
progression-free survival (PFS; 3-year PFS, 33% v 48%;
P , .001), and higher nonhematologic toxicities and treatment
discontinuation, regardless of ISS stage, chromosome abnormal-
ities, or treatment. Because performing a geriatric assessment can
be manpower and time consuming, a computer application was
also created to support clinicians.15
This frailty score was also validated in the phase III FIRST
(Frontline Investigation of Revlimid Plus Dexamethasone Versus
Standard Thalidomide) trial. Patients were categorized into three
severity groups. Of 1,517 patients, 17%were classified as fit, 30% as
intermediate, and 54% as frail. Similar breakdowns were observed
Table 1. Selected Studies in Elderly Patients With Myeloma
Regimen Patient Age $ 75 Years (%) ORR (%) Median PFS (months) OS P for Survival
MP 25* 50 13 66% at 3 years .25†
MPR 24* 68 14 62% at 3 years .81†
MPR-R 24* 77 31 70% at 3 years
Rd 35* 75 25.5 59% at 4 years .02‡
Rd18 36* 73 20.7 56% at 4 years
MPT 34* 62 21.2 51% at 4 years
Rd 37* 74 21 58% at 4 years .927§
MPR 39* 71 24 65% at 4 years .448§
CPR 36* 68 20 68% at 4 years
VD 50 73 14.7 49.8 monthsk .79
VTD 38 80 15.4 51.5 monthsk
VMP 37 70 17.3 53.1 monthsk
VP¶ 84# 64 14.0 60% at 2 years NA
VCP¶ 67# 67 15.2 70% at 2 years
VMP¶ 76# 86 17.1 76% at 2 years
Abbreviations: CPR, cyclophosphamide, prednisone, and lenalidomide; MP, melphalan plus prednisone; MPR, melphalan, prednisone, and lenalidomide; MPR-R,
melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance; MPT, melphalan, prednisone, and thalidomide; NA, not available; ORR, overall re-
sponse rate; OS, overall survival; PFS, progression-free survival; Rd, lenalidomide plus dexamethasone; Rd18, lenalidomide plus dexamethasone for 18 months; VCP,
bortezomib, cyclophosphamide, and prednisone; VD, bortezomib plus dexamethasone; VMP, bortezomib, melphalan, and prednisone; VP, bortezomib plus prednisone;
VTD, bortezomib, thalidomide, and dexamethasone.
*Age . 75 years.
†P 5 .25 for MPR-R v MPR and P 5 .81 for MPR-R v MP.
‡P 5 .02 for Rd v MPT.
§P 5 .927 for Rd v MPR and P 5 .448 for Rd v CPR.
kMedian values.
¶Low-dose regimens.
#Patients age $ 80 years: 21 (41%) in VP, 14 (27%) in VCP, and 15 (30%) in VMP arms.
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across treatment arms. Frail patients were older and had higher ISS
stage, worse performance status, higher lactate dehydrogenase
levels, and worse renal function than fit or intermediate patients.
Of note, fit patients had a significantly longer OS. This analysis
demonstrated predictive clinical outcomes in patients with newly
diagnosed MM, similar to the original scale. A majority of patients
fell into the frail category, demonstrating that this trial studied an
at-risk population with poor outcomes and unmet need.16
Treatment Options for Elderly Patients
MPT and VMP are the current standards of care for older pa-
tients with newly diagnosed MM.7,8 Recently, the European and US
regulatory authorities approved Rd for ASCT-ineligible patients.9
To date, there have been no prospective trials evaluating geriatric
assessment–driven treatments in elderly patients with newly diag-
nosed MM; the best strategy for frail patients remains to be defined.
The frequency of patients . 75 years of age was 22% to 30%
in the MPT and VMP regulatory trials,7,8 but in recent trials, this
percentage has been growing (Table 1). The optimal therapy for
elderly patients remains controversial; some favor less intensive
treatments (eg, doublet) to minimize complications, whereas others
support the use of full-dose therapies (eg, triplet) to maximize
survival benefit. Several trials, also conducted in the community-
based setting, have highlighted that a doublet therapy may be as
effective as a triplet, considering both efficacy and treatment-
related toxicities, particularly in patients . 75 years of age.
The MM-015 trial showed that MP plus lenalidomide
(MPR) followed by lenalidomide maintenance significantly
prolonged PFS (31 months) compared with MP (13 months;
P, .001) or MPR without maintenance (14 months; P, .001).
The rate of patients . 75 years of age in the trial was 24%.
Patients 65 to 75 years of age benefited the most, whereas those
. 75 years of age did not.17
Another phase III trial compared MPR versus cyclophos-
phamide, prednisone, and lenalidomide versus the doublet Rd in
elderly patients with newly diagnosed MM. The three-drug
alkylator-containing combinations were not superior to the
two-drug combination Rd. In addition, grade 3 or greater neu-
tropenia was significantly more frequent with MPR (64%) than
with Rd (25%; P , .001).18
In the randomized phase III UPFRONT (Velcade, Thalido-
mide, and Dexamethasone Versus Velcade and Dexamethasone
Versus Velcade, Melphalan, and Prednisone) trial, the doublet
bortezomib plus dexamethasone was as effective as the triplets
VMP and bortezomib, thalidomide, and dexamethasone and in-
duced a lower rate of nonhematologic adverse events (22% v 33%
to 37% with the three-drug combinations). Although all regimens
produced good outcomes, neither bortezomib, thalidomide, and
dexamethasone nor VMP offered any advantage over bortezomib plus
dexamethasone in patients treated in US community practice.19
A phase II trial evaluated three low–dose-intensity subcu-
taneous bortezomib-based treatments in patients age 75 years or
older. This study showed that bortezomib plus oral prednisone
(VP), VP plus cyclophosphamide, or VMP, followed by bortezomib
maintenance, were well tolerated and effective, with similar ef-
ficacy among VP, VP plus cyclophosphamide, and VMP. Rates
of toxicity, discontinuation, and early death resulting from tox-
icity were higher with VMP, particularly in frail patients (defined
according to the IMWG frailty score), who comprised 54% of
the study population.20
In the report accompanying this article, Hulin et al21 present
an updated analysis of the FIRST trial, additionally examining the
impact of age (# 75 v . 75 years), a stratification factor in the
study, on efficacy and safety of continuous Rd versus MPT and Rd
for 18 months (Rd18). After a median follow-up of approximately
4 years, continuous Rd reduced the risk of progression or death
compared with MPT, independent of age. However, in patients
. 75 years of age, median PFS was similar across treatment arms,
even though the risk of progression or death with continuous Rd
was reduced by 22% and 20% versus Rd18 and MPT, respectively,
and 4-year PFS was more than double compared with Rd18 and
MPT. Rd18 induced a similar PFS compared with MPT and
a marginally inferior OS compared with continuous Rd. Median
OS was longer with continuous Rd than MPT, including a 14-
month difference in patients . 75 years of age. In the continuous
Rd arm, grade 3 to 4 treatment-emergent adverse events were
similar between patients , 75 years of age or . 75 years of age;
however, older patients had more frequent lenalidomide dose
reductions. Age-based dose adjustments likely contributed to
a consistent safety profile between younger and older patients.
Importantly, 35% of patients . 75 years of age who received
continuous Rd continued to receive therapy for more than 2 years,
compared with 41% of patients # 75 years of age. This analysis
establishes continuous Rd as a new standard of care for patients
with newly diagnosed MM, regardless of age.
Table 2. Parameters to Consider in Decision-Making Process in Frail Patients With MM
Patient Characteristic Medical History Criteria to Start Treatment Disease Characteristic Goal of Treatment
Age Cardiovascular disease Myeloma-defining events: Cytogenetics Response (CR)
Functional and independence
status (ADL and IADL)
Thromboembolism Calcemia, renal impairment, anemia,
bone lesions
Stage (ISS) Disease control
Comorbidity (CCI)
Diabetes
or
Tumor aggressiveness Quality of life
Psychosocial status
Renal impairment
Biomarkers of malignancy:Peripheral neuropathy
$ 60% clonal bone marrow
plasma cells
Involved or uninvolved serum
FLC ratio $ 100
. One focal lesion on MRI
Abbreviations: ADL, Activity of Daily Living; CCI, Charlson comorbidity index; CR, complete response; FLC, free light chain; IADL, Instrumental Activity of Daily Living;
ISS, International Staging System; MM, multiple myeloma; MRI, magnetic resonance imaging.
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SUGGESTED APPROACHES TO MANAGEMENT
In a pooled analysis of 1,435 elderly patients enrolled in four Eu-
ropean phase III trials, advanced age ($ 75 years), occurrence of
severe adverse events, and drug discontinuation predicted shorter
survival in patients with newly diagnosedMM treatedwithMPalone
or in combination with thalidomide and/or bortezomib. Therefore,
avoiding treatment interruption and reducing the risk of adverse
effects in the initial phase of therapy are fundamental, and low–dose-
intensity treatments are appropriate options for these patients.22
Because the benefits obtained with new drug–based combi-
nations may be limited in older patients, an approach that includes
age and geriatric assessment should be adopted to appropriately
define and identify frail patients (Table 2). Some frail patients are
, 80 years of age, and conversely, some patients . 75 years of age
are not frail. Indeed, the presence of either functional decline on
ADL and IADL or the presence of comorbidities, rather than age
per se, may identify frail patients (Fig 1). Practical strategies are
necessary to recognize and appropriately manage frail patients to
avoid the undertreatment of fit patients and the overtreatment of
frail patients. Geriatric assessment is more accurate than tradi-
tional parameters such as age, performance status, and clinical
judgment; thus, it is the most adequate tool and should be in-
troduced into everyday clinical practice.23 As an alternative to a full
CGA, screening tools may be implemented to identify patients in
need of a deeper evaluation by a CGA.23,24 In MM, a simplified
geriatric assessment that includes ADL, IADL, and CCI was re-
cently introduced by the IMWG.15
On the basis of the results of a geriatric assessment, patients
can be stratified into a fit group, suitable for full-dose therapy with
three-drug combinations, or a frail group, requiring dose-adjusted
therapies. Treatment strategies for frail patients should have
minimal cumulative toxicity, which does not exacerbate any
pre-existing pathologic conditions. In this setting, two-drug
regimens have shown similar efficacy and limited toxicity as
compared with multidrug combinations. Additional studies are
needed to define more precise geriatric assessment–directed
treatment selection.
The medical history of each patient, including cardiovascular
disease, thromboembolism, diabetes, renal insufficiency, periph-
eral neuropathy, and psychosocial status, in addition to aggres-
siveness of disease, should be taken into account to decide the most
appropriate drugs, dosing, schedule, and route of administration
(oral, intravenous, or subcutaneous).25 In the case of our patient,
an 84-year-old (frail by definition) is considered at high risk for
toxicity and early discontinuation. Our patient received lenali-
domide plus reduced-dose dexamethasone. Treatment-related
toxicities were limited, and benefit was long lasting because
progression occurred after more than 60 months from diagnosis.
The age-based dexamethasone dose reduction and the reduction of
lenalidomide from 25 to 10 mg during maintenance likely con-
tributed to good tolerability and an extended duration of treatment.
Furthermore, lenalidomide has the advantage of oral administration,
thus improving compliance and adherence to therapy.
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